Lorlatinib, a novel kinase inhibitor, has garnered attention in the industry because it has the potential to treat cancers.The PDUFA date, as the FDA (FDA) prepares to review the NDA (NDA) for lorlatinib, is a milestone about which people are eager to understand the implications and expectations.

The aim of this article is to provide a overview of the lorlatinib PDUFA, emphasizing aspects and discussing four needs within the context of the process.Goals refer to the outcomes of the analysis and adjustment.Constrains outline the limitations and requirements for the analysis and adjustment.

Skills involve the expertise and methods used to perform the analysis and adjustment.Workflow describes the process for performing the analysis, adjusting the structure, and providing the content in format.Firstly, content will be to analysis.

Furthermore, modifications are to be made to the composition of the expressions in accordance with their grammatical structure.Moreover, expressions are to be converted from active mode to passive mode.Fourthly, simple expressions are to be converted into complex expressions.eventually, the modified material are to be provided in JSon layout.